My expertise is in general Hematology-Oncology and my research interests focus on stem cell biology. I have focused on biology of engraftment in non-myeloablative and minimally myeloablative syngeneic and allogeneic murine models. I have evaluated a number of factors related to optimal engraftment including cell dose, timing of stem cell infusion, degree of MHC compatibility, and variations in preparative regimens. I have a clinical interest in the application of minimal ablation/cellular immunotherapy approaches to a variety of different diseases. I have accomplished clinical studies in other general oncology areas including head and neck cancer, germ cell cancers, as well as hematologic malignancies. I am currently on the Editorial Board for the Journal of Cellular Biochemistry and the Journal of Intensive Care Medicine. I have served as Program Author and Associate Editor-Hematology Section for the Medical Knowledge Self Assessment Program (MKSAP) and Section Editor-Hematology for Irwin and Rippe’s Intensive Care Medicine. My ASCO Education Committee work has included Leader for the Hematologic Malignancies track and Member of the Clinical Therapeutics and Transplantation tracks.
Stem cell transplantation, head and neck cancers, genitourinary cancer, blood disorders
David I Smith received his PhD in Biochemistry from the University of Wisconsin in 1978. He did post-doctoral research first at the Albert Einstein College of Medicine and then at the University of California, Irvine. His first faculty position was in the Department of Molecular Biology and Genetics at Wayne State University in Detroit. In 1996 he joined the Department of Laboratory Medicine and Pathology at the Mayo Clinic as a Professor. He is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. The goal of this Group is to analyze new technologies for their potential impact on basic research and the clinical translation of these results. His laboratory studies the common fragile sites which are regions of profound genomic instability found in all individuals. His group is also studying the various ways that human papillomavirus is involved in the development of different cancers. His group uses different next-generation sequencing technologies to analyze where HPV has integrated into the human genome in these different cancers and the resulting genomic disruptions caused by these integrations.
Oropharyngeal cancer, Long noncoding RNA.
Dr. Leong is board certified in surgery and is a nationally recognized expert in melanoma. He specializes in selective sentinel lymph node dissections, and immunotherapy for patients with advanced melanoma. Dr. Leong has lectured nationally and internationally on new advances in the treatment of malignant melanoma and the use of selective sentinel lymphadenectomy. As Associate Director of CPMC’s Center for Melanoma Research and Treatment, Dr. Leong collaborates with other investigators including Dr. Mohammed Kashani-Sabet on a new integrated research program at CPMCRI aimed at developing novel combination therapies for aggressive and metastatic tumors, including melanomas.
Melanoma, sentinel lymph node dissections, and immunotherapy
A world-renowned scientist, Dr. Charpentier is widely recognized for her seminal research contributions to the discovery and development of the CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 (CRISPR associated protein 9) gene-editing system. This system and Dr. Charpentier’s ongoing research continues to contribute to groundbreaking progress in the fields of molecular biology and genetics.
CRISPR-Cas9, RNA-Mediated Adaptive Immunity (CRISPR-Cas), Toxin-antitoxin (TA) systems
Addi Lang is the Founder of the FOREVER CHANGED campaign in South Africa. FOREVER CHANGED is a campaign focused on cancer prevention, early detection, patient rights, doctor-patient negligence and messages of hope to all women. Addi spreads the hard reality of a cancer diagnosis and how it fundamentally changes a woman’s life forever. However, Addi emphasizes that, “how you cope with this change is defined by how you approach it. Change is always a challenge, but it can also positively transform your life. Take responsibility for your health and own it! “ FOREVER CHANGED is represented by the butterfly to reflect the change and transformation that happen when any woman is touched by cancer. Life is never the same again once diagnosed. Addi has also defined herself and others fighting the disease as warriors – people who have a battle to fight but are courageous and capable. The FOREVER CHANGED initiative helps enable women to have the courage to fight this disease, feeling armed with all the information and knowledge they need, whilst still having hope. The MEDIA STATEMENT ISSUED BY ICECURE MEDICAL LTD, 12th July, 2018 stated, “On behalf of IceCure Medical Ltd, we applaud Forever Changed for their dedicated approach to ensure that breakthrough cancer technology and treatments become known not only in South Africa, but the African Continent, and because the campaign empowers through first-hand experiences and fact-driven education”. The FOREVER CHANGED initiative also embraces music as a way of coming together to raise awareness and show support. FOREVER CHANGED hopes to inspire women to find the courage they need to do the same, for themselves and for each other. More about Forever Campaign and Addi Lang: http://ramify.biz/2018/06/27/mediacom-and-forever-changed-partnership-putting-cancer-survivors-first-in-sas-workplace/ https://www.cnbcafrica.com/videos/2018/07/13/addressing-cancer-in-the-workplace/ https://web.facebook.com/notes/branded-communication/know-your-health-rights/1808526239229389/ https://www.mymed.com/latest-news/the-fundamental-impact-of-cancer-a-life-forever-changed
As the executive producer of the Forever Changed Documentary, Co founder of The Forever Changed Global Awareness Campaign, Mr. David Salomon is well versed in the understanding of nutrition and cancer. He has completed 3 years of intensive research due to his life partner’s late stage cancer diagnosis in 2014. Having studied conventional and holistic approaches to cancer. Mr. Salomon has completed professional studies in Israel, about cancer technology and research with medical breakthroughs at 3 leading medical institutions. Speaking from a scientific perspective on nutrition vs cancer enables him to provide information that is not usually addressed in the standard medical field of oncology. Present – Forward Integration Chemicals (Pty) Ltd. Owner As a chemical engineer with extensive experience in research and manufacturing in large and small corporations. 2014 present – Co Founder of Forever Changed Global Awareness Campaign Accomplishments: Winner - Standard Bank Businessman of the Year Award – 1991/2. Nomination - SA Jewish Report Award – Humanitarian – 2017. Global clients include: Lion Match Group SA, Impala Platinum Refinery SA , Merck Germany, Degussa Germany and Advanced Formulated Compounds, Atlanta, USA. He released the latest clinical trials for Ice Cure Medical at Forever Changed's Press Meet. The MEDIA STATEMENT ISSUED BY ICECURE MEDICAL LTD, 12th July, 2018 stated, “On behalf of IceCure Medical Ltd, we applaud Forever Changed for their dedicated approach to ensure that breakthrough cancer technology and treatments become known not only in South Africa, but the African Continent, and because the campaign empowers through first-hand experiences and fact-driven education”. Skills: Chemical technology IP and Patent Holder, Plant Commissioning, Research and Development, Management at Board Level, Education 1960 – 1964 – Aloney Yitzchak, Israel Education: Higher, Technion Institute of Technology, University, Israel 1969 – 1972
Dr. Alireza Heidari, Ph.D., D.Sc. is a Postdoctoral Research Fellow in Chemistry. Furthermore, he has double postdocs in Project Management and also in Nanochemistry and Molecular Structure Theory. He has participated at more than one hundred reputed international conferences, seminars, congresses, symposiums, and forums around the world as yet. Dr. Heidari has been a senior advisor in various industry and factories. He is an expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than nine hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than three hundreds reputed international academic–scientific–research institutes around the world. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.
Dimitrios H. Roukos, MD, Ph.D., is Professor of Surgery – Precision Cancer Medicine and Founding director of “Centre for Biosystems and Genome Network Medicine” in the Ioannina University, School of Medicine. His translational and clinical research from traditional and single gene investigation to molecular networks and clinical cancer genome NGS analysis has been recognized by the international scientific community. He has published > 236 PubMed papers with recent focus on NGS conventional and breakthrough genome analysis (> 80 articles) and more recently in precision cancer medicine (31 articles). These publications have received more than 8420 citations with h-index: 72 (Scopus). He is a reviewer in many high impact journals including some with impact factor (IF) >30, evaluator in innovative research projects (EU, France, Belgium, Luxemburg, Poland), and member in the editorial board of 25 international journals with IF. He has been invited as a speaker in many international and world congresses
Daniela Capdepon MD, graduate of the University F. Medical Barceló in 2001 with honors and highest academic average. Make residency in Internal Medicine at the Municipal hospital and COBA oriented Graduate Clinical Oncology from 2002 to 2004. Then I began to study the specialty of Clinical Oncology at the University of Salvador, trained in gastric tumors in Udaondo Hospital, Hospital Marie Curie Cancer Center and Henry Moore at where we learned to prepare and deliver chemotherapies and concurrences to form the pallium Center for palliative treatment of pain. Graduated in the specialty of clinical oncologist and palliative medicine subspecialty in Pain in 2006 of Salvador University, Buenos Aires. Oncologist at Work as outpatient and outpatient chemotherapy treatments made in Municipal Hospital and Italian Society of Zarate and Campana. Fellow in Fundaleu as subinvestigadora in Oncohematology and where do my training in liquid tumors, LLC, ALL MM, NHL LH. During 2006-2007. In 2008 I built my own Cancer Center, of which I am the owner and medical director, is Campana Cancer Center, where cancer care is done in outpatient chemotherapy treatments and pain and palliative treatments. Together with a specialized team that works with me. We also conduct Cancer Center, clinical research protocols in various tumors. Starting a new labor stage in the province of Entre Rios as oncologist responsible for the service in Peru Galarza General Hospital. And St. Joseph Medical.